Advertisement

European Journal of Nuclear Medicine

, Volume 12, Issue 9, pp 447–454 | Cite as

Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostate

  • G. M. Blake
  • M. A. Zivanovic
  • A. J. McEwan
  • D. M. Ackery
Article

Abstract

Strontium kinetics were investigated in a group of 14 patients receiving 89Sr palliation for metastatic bone disease secondary to prostatic carcinoma. Using 85Sr as a tracer, total body strontium retention R(t) was monitored for a 3 month period following 89Sr administration, and at 90 days was found to vary from 11% to 88% and to correlate closely with the fraction of the skeleton showing scintigraphic evidence of osteoblastic metastatic involvement. Strontium renal plasma clearance varied from 1.6 l/day to 11.6 l/day, and in nine patients was significantly reduced compared with values found in healthy adult men, probably due to increased renal tubular reabsorption associated with the disturbance of calcium homoeostasis. Renal clearance rate was the principal factor determining R(t) for t<6 days, and was an important secondary factor at later times. Over the interval 30 days t<90 days, R(t) was closely fitted by the power law function R(t)=R30 (t/30)-b, with R30 and b showing the close correlation expected from the effect of R(t) on strontium recycling. The correction of the data for this effect to determine the true skeletal release rate is described. Measurement of localized strontium turnover in individual metastatic deposits from whole body profiles and scintigraphic images gave retention curves that typically rose to a plateau by 10 days after therapy, and then decreased very slowly. In contrast, retention curves for adjacent normal trabecular bone showed more rapid turnover, peaking at 1 day and subsequently decreasing following a t-0.2 power law function. The changes in strontium kinetics found in metastatic bone disease are favourable to the objectives of 89Sr therapy.

Key words

89Sr therapy Prostatic carcinoma Strontium kinetics Metastatic bone disease 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bishop M, Harrison GE, Raymond WHA, Sutton A, Rundo J (1960) Excretion and retention of radioactive strontium in normal men following a single intravenous injection. Int J Rad Biol 2:125–142Google Scholar
  2. Cohn SH, Spencer H, Samachson J, Robertson JS (1962) The turnover of strontium-85 in man as determined by whole-body counting. Rad Res 17:173–185Google Scholar
  3. Comar CL (1967) Some principles of strontium metabolism: implications, applications, limitations. In: Lenihan JMA, Loutit JF, Martin JH (eds) Strontium Metabolism. Academic Press, London, pp 17–31Google Scholar
  4. Firusian N, Mellin P, Schmidt CG (1976) Results of strontium-89 therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: a preliminary report. J Urol 116:764–768Google Scholar
  5. Harrison GE, Raymond WHA, Tretheway HC (1955) The metabolism of strontium in man. Clin Sci 14:681–695Google Scholar
  6. Harrison GE, Sutton A (1967) Ratio of the faecal to urinary clearance of strontium in man. In: Lenihan JMA, Loutit JF, Martin JH (eds) Strontium Metabolism. Academic Press, London, pp 161–166Google Scholar
  7. ICRP (1979) Metabolic data for strontium. In: ICRP Publication 30: Limits for intakes of radionuclides by workers, Part 1. Pergamon Press, Oxford, pp 77–78Google Scholar
  8. Likhtarev IA, Dobroskok IA, Ilyin LA, Krasnoschekova GP, Likhtareva TM, Smirnov BI, Sobolev EP, Shamov VP, Shapiro EL (1975) A study of certain characteristics of strontium metabolism in a homogeneous group of human subjects. Health Phys 28:49–60Google Scholar
  9. Ludwig GD (1962) Hypocalcaemia and hypophosphataemia accompanying osteoblastic osseous metastases: studies of calcium and phosphate metabolism and parathyroid function. Ann Int Med 56:676–677 (abstr)Google Scholar
  10. Marshall JH, Lloyd EL, Rundo J, Liniecki J, Marroti G, Mays CW, Sissons HA, Snyder WS (1973) Alkaline earth metabolism in adult man. Health Phys 24:125–221Google Scholar
  11. McEwan AJ, Zivanovic MA, Blake GM, Buchanan RB, Ackery DM (1986) Sr-89 Therapy: clinical response in metastatic bone discase. Nucl Med Commun 7:293 (abstr)Google Scholar
  12. Mundy GR, Ibbotson KJ, D'Souza SM, Simpson EL, Jacobs JW, Martin TJ (1984) The hypercalcemia of cancer. N Engl J Med 310:1718–1727Google Scholar
  13. Pecher C (1942) biological investigations with radioactive calcium and strontium: preliminary report on the use of radioactive strontium in the treatment of bone cancer. University of California Publications in Pharmacology 11:117–149Google Scholar
  14. Percival RC, Urwin GH, Watson ME, Harris S, Yates AJP, Williams JL, Beneton M, Kanis JA (1986) Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol (in press)Google Scholar
  15. Ralston S, Fogelman I, Gardner MD, Boyle IT (1982) Hypercalcaemia and metastatic bone disease: is there a causal link? Lancet II:903–905Google Scholar
  16. Ralston SH, Fogelman I, Gardner MD, Dryburgh FJ, Cowan RA, Boyle IT (1984) Hypercalcaemia of malignancy: evidence for a non-parathyroid humoral agent with an effect on renal tubular handling of calcium. Clin Sci 66:187–191Google Scholar
  17. Raskin P, McClain CJ, Medsger TA (1973) Hypocalcemia associated with metastatic bone disease. Arch Intern Med 132:539–543Google Scholar
  18. Reeve J, Hesp R (1976) A model-independent comparison of the rates of uptake and short term retention of 47Ca and 85Sr in the skeleton. Calcif Tissue Res 22:183–189Google Scholar
  19. Reeve J, Wootton R, Hesp R (1976a) A new method for calculating the accretion rate of bone calcium and some observations on the suitability of strontium-85 as a tracer for bone calcium. Calcif Tissue Res 20:121–135Google Scholar
  20. Reeve J, Hesp R, Wootton R (1976b) A new tracer method for the calculation of rates of bone formation and breakdown in osteoporosis and other generalised skeletal disorders. Calcif Tissue Res 22:191–206Google Scholar
  21. Robinson RG (1986) Radionuclides for the alleviation of bone pain in advanced malignancy. Clinics in Oncology Volume 5/ Number 1:39–49Google Scholar
  22. Schulert AR, Peets EA, Laszlo D, Spencer H, Charles M, Samachson J (1959) Comparative metabolism of strontium and calcium in man. Int J Applied Radiation and Isotopes 4:144–153Google Scholar
  23. Shimmins J, Smith DA, Nordin BEC, Burkinshaw L (1967) A comparison between calcium-45 and strontium-85 absorption, excretion and skeletal uptake. In: Lenihan JMA, Loutit JF, Martin JH (eds) Strontium Metabolism. Academic Press, London, pp 149–159Google Scholar
  24. Smallridge RC, Wray HL, Schaaf M (1981) Hypocalcemia with osteoblastic metastases in a patient with prostate carcinoma. A cause of secondary hyperparathyroidism. Am J Med 71:184–188Google Scholar
  25. Spencer H, Li M, Samachson J, Laszlo D (1960) Metabolism of strontium-85 and calcium-45 in man. Metabolism 9:916–925Google Scholar
  26. Sudell CJ, Blake GM, Gossage AAR, Cullen DR, Munro DS (1985) Adrenal scintigraphy with 75Se selenonorcholestenol: a review. Nucl Med Commun 6:519–527Google Scholar
  27. Tothill P, Smith MA, Cohn SH (1983) Whole-body and part-body turnover of 85Sr in Paget's disease. Phys Med Biol 28:149–159Google Scholar
  28. Urwin GH, Percival RC, Galloway J, Guilland-Cumming DF, Lawson-Matthew PJ, Williams JL, Kanis JA (1986) endocrinology of disseminated prostatic carcinoma. Bone and Tooth Society, Spring Meeting April 1986 (abstract to be published in Bone)Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • G. M. Blake
    • 1
  • M. A. Zivanovic
    • 1
  • A. J. McEwan
    • 1
  • D. M. Ackery
    • 1
  1. 1.Wessex Regional Department of Nuclear MedicineSouthampton General HospitalSouthamptonUK

Personalised recommendations